Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: Implications for cancer therapy

American Journal of Pathology

Volumn 175, Issue 1, 2009, Pages 314-323

  Gjerstorff, Morten ^a   Burns, Jorge S ^a,b   Nielsen, Ole ^b   Kassem, Moustapha ^a,b   Ditzel, Henrik ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BAGE ANTIGEN; CANCER GERMLINE ANTIGEN; DNA METHYLTRANSFERASE INHIBITOR; GAGE ANTIGEN; HAGE ANTIGEN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; SSX1 9 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; XAGE 1 ANTIGEN;

ACETYLATION; ADULT; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL CLONE; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; METHYLATION; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SARCOMA CELL; TUMOR XENOGRAFT;

EID: 67649950306     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080893     Document Type: Article

References (40)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625
2. Fijak M, Meinhardt A: The testis in immune privilege. Immunol Rev 2006, 213:66-81
3. Gjerstorff MF, Harkness L, Kassem M, Frandsen U, Nielsen O, Lutterodt M, Mollgard K, Ditzel HJ: Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Hum Reprod 2008, 23:2194-2201
4. Kirkin AF, Dzhandzhugazyan KN, Zeuthen J: Cancer/testis antigens: structural and immunobiological properties. Cancer Invest 2002, 20:222-236
5. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002, 188:51-64
6. Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E: Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007, 120:2178-2184
7. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E: T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007, 7:9
8. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S: Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007, 104:12837-12842
9. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190:1669-1678
10. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230
11. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jager D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A: Recombinant vaccinia/fowlpox NYESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006, 103:14453-14458
12. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS: Recombinant NYESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004, 101:10697-10702
13. Burgdorf SK, Fischer A, Claesson MH, Kirkin AF, Dzhandzhugazyan KN, Rosenberg J: Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res 2006, 25:201-206
14. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC: Identification of HLA-A*03. A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000, 244:59-67
15. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC: HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3. Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998, 161:6970-6976
16. De Smet C, Loriot A, Boon T: Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004, 24:4781-4790
17. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996, 93:7149-7153
18. Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M: Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 2002, 25:16-26
19. Loriot A, De Plaen E, Boon T, De Smet C: Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006, 281:10118-10126
20. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19:7327-7335
21. Wischnewski F, Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4:339-349
22. James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006, 25:6975-6985
23. Karpf AR: A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006, 1:116-120
24. Claus R, Almstedt M, Lubbert M: Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol 2005, 32:511-520
25. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, Kassem M: Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004, 23:5095-5098
26. Burns JS, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, Kassem M: Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res 2005, 65:3126-3135
27. Burns JS, Abdallah BM, Shroder HD, Kassem M: The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma? Histol Histopathol 2008, 23:1229-1240
28. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I: Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005, 65:11459-11468
29. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007, 25:371-379
30. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7:967-976
31. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S: Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103
32. Kassem M, Mosekilde L, Eriksen EF: 1,25-dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 1993, 8:1453-1458
33. Gjerstorff MF, Johansen LE, Nielsen O, Kock K, Ditzel HJ: Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 2006, 94:1864-1873
34. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006, 103:11160-11165
35. Zhang J, Yu J, Gu J, Gao BM, Zhao YJ, Wang P, Zhang HY, De Zhu J: A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene. Cell Res 2004, 14:283-294
36. De Plaen E, Naerhuyzen B, De Smet C, Szikora JP, Boon T: Alternative promoters of gene MAGE4a. Genomics 1997, 40:305-313
37. Graf T, Stadtfeld M: Heterogeneity of embryonic and adult stem cells. Cell Stem Cell 2008, 3:480-483
38. D'Alessio AC, Weaver IC, Szyf M: Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. Mol Cell Biol 2007, 27:7462-7474
39. Momparler RL: Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine). Semin Oncol 2005, 32:443-451
40. Taddei A, Roche D, Bickmore WA, Almouzni G: The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 2005, 6:520-524